Navigation Links
Chemo Patients Pose Potential Public Health Risk
Date:9/19/2013

NEWPORT, R.I., Sept. 19, 2013 /PRNewswire-iReach/ -- In its second edition of "Safe Management of Wastes from Health-Care Activities," released in August, the World Health Organization (WHO) singled out contact with residual amounts of chemotherapy drugs as a significant risk requiring collection, containment and proper disposal in order to avoid exposure "through contact with body fluids and secretions [urine, feces and vomit] of patients undergoing chemotherapy."

Genotoxic/cytotoxic compounds, most commonly found in chemotherapy drugs, work by either mutating or killing cells. Unlike poisons, which can be safe when exposure is limited to tiny amounts, genotoxins/cytotoxins act more like "chemical germs," where even minimal exposure can cause a devastating chain reaction. The risk from contact to an otherwise healthy person is especially heightened when there is a significant amount of cell development happening — for example, among children and women of childbearing age.

According to the WHO report, any wastes produced by these patients within 48 hours of drug administration, and in some cases for up to a week, should be considered genotoxic.

Despite the otherwise well-regulated and well-managed handling of dangerous medical waste, chemotherapy patients treated with any of more than two dozen different chemotherapy drugs who return home after outpatient treatment can inadvertently but easily expose others to genotoxic contamination through seemingly benign occurrences such as urine splashed on a bathroom floor, clean up after an episode of vomiting, or the handling of bed sheets or a bedpan for a patient unable to use a bathroom.

The WHO report address what many in the field of chemotherapy-based treatment have long acknowledged as a dangerous "blind spot."
The human body can only destroy a portion of these genotoxic drugs. The rest passes out of the patient in urine, feces, vomit, or even sweat. The waste will still have enough dangerous drug to kill developing cells and/or cause mutations in vulnerable members of our population, especially fetuses and babies.

The WHO has done a great public service by stepping up and publicly declaring what many of us in the field have long known — this is a serious risk.

WHO core principles "require that everyone associated with financing and supporting health-care activities should provide for the costs of managing health-care waste. This is the duty of care. Manufactures also share a responsibility to take waste management into account in the development and sale of their products and services."

The WHO goes on to identify those who have a special responsibility to ensure safe collection, containment and disposal of these wastes, placing much of that responsibility with the chief pharmacist. "The chief pharmacist also has the special responsibility of ensuring that genotoxic products are used safely, and that genotoxic waste is managed safely," according to the WHO.

Jim Mullowney is the founder and CEO of Newport-based Pharma-Cycle Inc

Media Contact: Jim Mullowney, Pharma-Cycle, Inc., 617-755-0883, jmullowney@pharma-cycle.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Pharma-Cycle, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Big Pharma to Come Together at ChemOutsourcing 2013 in Long Branch, New Jersey, Sept 16-19
2. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
3. ChemOutsourcing Announces 100 CMO and CRO Exhibitors for September 2013 Show in Long Branch, New Jersey
4. ChemOutsourcing Announces 30 Pharma Company Presenters for September 2013 Outsourcing Show in New Jersey
5. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
6. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
7. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
8. Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
9. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
10. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. ... appointed Paul M. Bisaro as Impax,s President ... Company,s Board, effective March 27, 2017. Mr. Bisaro will ... as Interim President and Chief Executive Officer since December ... generic and branded pharmaceutical experience, Mr. Bisaro, 56, is ...
(Date:3/27/2017)... 2017 Invivotek, LLC, a Genesis Biotechnology Group ... pharmacology contract research organization (CRO), announced the completion ... expanded preclinical research facility in Hamilton, New ... renewable energy source to reduce costs and lessen the ... Genesis Solar Farm follows Invivotek,s recent expansion from a ...
(Date:3/24/2017)... , March 24, 2017  Zymo Research ... and Hamilton Robotics, Inc., who designs, manufactures ... ongoing collaboration that teams Zymo Research,s DNA ... and DNA extraction products with Hamilton,s high-throughput ... optimized methods for microbiomics and RNA isolation ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to 2015, ... for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat the ... proposes a tax on prescription opioids to fund drug rehabilitation and prevention services.(3) ...
(Date:3/26/2017)... ... March 26, 2017 , ... ... receive the RealSelf 100 Award, a prestigious award honoring the top influencers on ... to find and connect with doctors and clinics. , In 2016, more than ...
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, Inc., ... and hazardous and non-hazardous materials announced today the acquisition of privately owned ... add four additional processing facilities and a vast array of additional technologies, services, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA Senior ... not obey the rules Congress has directed the CBO to follow. The CBO itself ... would restore. Yet, it estimates a reduction in employer-based coverage due to the GOP ...
Breaking Medicine News(10 mins):